Author's response to reviews

Title: FemZone Trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

Authors:

Peter A Fasching (peter.fasching@uk-erlangen.de)
Sebastian M Jud (sebastian.jud@uk-erlangen.de)
Maik Hauschild (maik.hauschild@frauenklinik-rheinfelden.de)
Sherko Kuemmel (S.Kuemmel@kliniken-essen-mitte.de)
Martin Schuette (martin.schuette@uk-essen.de)
Matthias Warm (warmm@kliniken-koeln.de)
Volker Hanf (Volker.Hanf@klinikum-fuerth.de)
Dieter Grab (frauenklinik.kh@klinikum-muenchen.de)
Jutta Krockner (j.krockner@sana-kl.de)
Elmar Stickeler (elmar.stickeler@uniklinik-freiburg.de)
Rolf Kreienberg (r.kreienberg@t-online.de)
Thomas Mueller (frauenklinik@klinikum-hanau.de)
Thorsten Kuehn (t.kuehn@klinikum-esslingen.de)
Christopher Wolf (dchristopherwolf@arcor.de)
Steffen Kahlert (stefen.kahlert@med.uni-muenchen.de)
Stefan Paepke (stefan.paepke@lrz.tu-muenchen.de)
Michael Berghorn (michael.berghorn@akh-celle.de)
Mathias Muth (mathias.muth@novartis.com)
Monika Baier (monika.baier@novartis.com)
Birgit Wackwitz (birgit.wackwitz@novartis.com)
Ruediger Schulz-Wendtland (Ruediger.Schulz-Wendtland@uk-erlangen.de)
Matthias W Beckmann (fk-direktion@uk-erlangen.de)
Michael P Lux (Michael.lux@uk-erlangen.de)

Version: 4  Date: 23 December 2013

Author's response to reviews:

Comment 1) Primary endpoint was NOT according to RECIST. This should be changed in the manuscript as marked in the attached document.

Reply 1) This was changed throughout the manuscript.

Comment 2) Since most patients received surgery, pT data must be available somewhere. These data should be added to the manuscript.

Reply 2) This data was added as Table 3 and Supplementary Table 2. Description of these Tables were added in the manuscript.
3) Since CTCAE version for toxicity was used, the table on toxicities should be divided in grade 1-2 versus grade 3-4 toxicity, or at least some information on grading should be given.

Reply 3) The Toxicity Table was changed according to this request, additionally clinically most important AEs are now listed as single categories.

--------------------------------------------

Comment 4) Some minor edits as marked in the document.

Reply 4) Done, thanks. Concerning the last comment with regard to correlation between clinical and pathological tumor size, this sentence does not make sense any more and was omitted, as mean pathological tumor sizes were provided now in Table 2 and supplementary table 2.